| Literature DB >> 24911965 |
Wen-Ling Lin1, Chen-June Seak1, Jiunn-Yih Wu2, Yi-Ming Weng1, Hang-Cheng Chen2.
Abstract
BACKGROUND: Previous studies have analyzed factors associated with renal infarction so that patients can be provided with earlier diagnosis and treatment. However, the factors associated with development of chronic kidney disease (CKD) following renal infarction are unknown.Entities:
Mesh:
Year: 2014 PMID: 24911965 PMCID: PMC4049636 DOI: 10.1371/journal.pone.0098880
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of study subjects admitted to the emergency department for renal infarction (n = 40).
| Characteristic | |
| Age (years), mean ± SD | 53.18±15.10 |
| Gender, n (%) | |
| Female | 11 (27.5) |
| Male | 29 (72.5) |
| Previous renal infarction, n (%) | |
| No | 39 (97.5) |
| Yes | 1 (2.5) |
|
| |
| Aspirin, n (%) | |
| No | 26 (65.0) |
| Yes | 14 (35.0) |
| Warfarin, n (%) | |
| No | 34 (85.0) |
| Yes | 6 (15.0) |
| Amiodarone, n (%) | |
| No | 39 (97.5) |
| Yes | 1 (2.5) |
| Clopidogrel, n (%) | |
| No | 40 (100.0) |
| Yes | 0 (0.0) |
| Steroid, n (%) | |
| No | 39 (97.5) |
| Yes | 1 (2.5) |
| Chinese herb, n (%) | |
| No | 39 (97.5) |
| Yes | 1 (2.5) |
| Hormone replacement therapy, n (%) | |
| No | 38 (95.0) |
| Yes | 2 (5.0) |
|
| |
| Duration (h) of symptoms/signs before admission, median (IQR) | 24.0 (12.0–84.0) |
| Fever, n (%) | |
| No | 34 (85.0) |
| Yes | 6 (15.0) |
| Chills, n (%) | |
| No | 39 (97.5) |
| Yes | 1 (2.5) |
| Abdominal pain, n (%) | |
| No | 6 (15.0) |
| Yes | 34 (85.0) |
| Abdominal fullness, n (%) | |
| No | 36 (90.0) |
| Yes | 4 (10.0) |
| Dyspnea, n (%) | |
| No | 36 (90.0) |
| Yes | 4 (10.0) |
| Flank pain, n (%) | |
| No | 23 (57.5) |
| Yes | 17 (42.5) |
| Back pain, n (%) | |
| No | 37 (92.5) |
| Yes | 3 (7.5) |
| Nausea, n (%) | |
| No | 26 (65.0) |
| Yes | 14 (35.0) |
| Vomiting, n (%) | |
| No | 28 (70.0) |
| Yes | 12 (30.0) |
| Hematuria, n (%) | |
| No | 39 (97.5) |
| Yes | 1 (2.5) |
| Oligouria, n (%) | |
| No | 40 (100.0) |
| Yes | 0 (0.0) |
| Anuria, n (%) | |
| No | 40 (100.0) |
| Yes | 0 (0.0) |
| Etiology, n (%) | |
| Cardiac or other embolism | 18 (45.0) |
| Thrombosis or coagulation dysfunction | 16 (40.0) |
| Spontaneous renal artery dissection | 1 (2.5) |
| Idiopathic | 5 (12.5) |
|
| |
| eGFR at admission (mL/min per 1.73 m2), median (IQR) | 66.70±31.03 |
|
| |
| APACHE II, median (IQR) | 7.0 (4.0–10.0) |
| SOFA, median (IQR) | 1.0 (0.0–2.0) |
| ASA, median (IQR) | 2.0 (1.0–3.0) |
| SAPS II, median (IQR) | 15.0 (13.0–19.0) |
Mean (±SD) eGFR and Cr of patients at admission and at 3 to 12 months after discharge (n = 40).
| Parameter | At admission | 3 to 12 months after discharge | Difference |
|
| eGFR (mL/min/1.73 m2) | 66.7±31.0 | 70.5±28.5 | 3.8±11.1 | 0.035 |
| Cr (mg/dL) | 1.35±0.64 | 1.23±0.38 | −0.12±0.46 | 0.115 |
Paired t-test.
Figure 1Changes in eGFR for (A) all patients (n = 40), and those evaluated at (B) 3 months after discharge (n = 11), (C) 6 months after discharge (n = 2), (D) 9 months after discharge (n = 6), and (E) 12 months after discharge (n = 21).
Univariate analysis of risk factors associated with chronic kidney disease at follow-up among patients admitted for renal infarction.
| Characteristic | CKD/Total (%) |
| OR (95% CI) |
|
| Age (years) | ||||
| ≦50 | 2/18 (11.1) | 0.009 | 1.00 (reference) | |
| >50 | 11/22 (50.0) | 8.00 (1.48–43.40) | 0.016 | |
| Gender | ||||
| Female | 3/11 (27.3) | 1.000‡ | 1.00 (reference) | |
| Male | 10/29 (34.5) | 1.40 (0.30–6.49) | 0.665 | |
| Previous renal infarction | ||||
| No | 13/39 (33.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 0/1 (0.0) | NA | 0.981 | |
|
| ||||
| Aspirin | ||||
| No | 6/26 (23.1) | 0.155‡ | 1.00 (reference) | |
| Yes | 7/14 (50.0) | 3.33 (0.83–13.37) | 0.089 | |
| Warfarin | ||||
| No | 11/34 (32.4) | 1.000‡ | 1.00 (reference) | |
| Yes | 2/6 (33.3) | 1.05 (0.17–6.61) | 0.962 | |
| Amiodarone | ||||
| No | 13/39 (33.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 0/1 (0.0) | NA | 0.981 | |
| Steroid | ||||
| No | 12/39 (30.8) | 0.325‡ | 1.00 (reference) | |
| Yes | 1/1 (100.0) | NA | 0.982 | |
| Chinese herb | ||||
| No | 13/39 (33.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 0/1 (0.0) | NA | 0.981 | |
| Hormone therapy | ||||
| No | 12/38 (31.6) | 1.000‡ | 1.00 (reference) | |
| Yes | 1/2 (50.0) | 2.17 (0.13–37.64) | 0.596 | |
|
| ||||
| Duration (h) of symptoms/signs before admission | ||||
| ≦24 | 11/24 (45.8) | 0.027 | 1.00 (reference) | |
| >24 | 2/16 (12.5) | 0.17 (0.03–0.91) | 0.039 | |
| Fever | ||||
| No | 12/34 (35.3) | 0.643‡ | 1.00 (reference) | |
| Yes | 1/6 (16.7) | 0.37 (0.04–3.51) | 0.384 | |
| Chills | ||||
| No | 13/39 (33.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 0/1 (0.0) | NA | 0.981 | |
| Abdominal pain | ||||
| No | 0/6 (0.0) | 0.152‡ | 1.00 (reference) | |
| Yes | 13/34 (38.2) | NA | 0.952 | |
| Abdominal fullness | ||||
| No | 12/36 (33.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 1/4 (25.0) | 0.67 (0.06–7.11) | 0.737 | |
| Dyspnea | ||||
| No | 11/36 (30.6) | 0.584‡ | 1.00 (reference) | |
| Yes | 2/4 (50.0) | 2.27 (0.28–18.27) | 0.440 | |
| Flank pain | ||||
| No | 5/23 (21.7) | 0.091 | 1.00 (reference) | |
| Yes | 8/17 (47.1) | 3.20 (0.81–12.65) | 0.097 | |
| Back pain | ||||
| No | 12/37 (32.4) | 1.000 ‡ | 1.00 (reference) | |
| Yes | 1/3 (33.3) | 1.04 (0.09–12.66) | 0.974 | |
| Nausea | ||||
| No | 9/26 (34.6) | 1.000‡ | 1.00 (reference) | |
| Yes | 4/14 (28.6) | 0.76 (0.18–3.11) | 0.698 | |
| Vomiting | ||||
| No | 9/28 (32.1) | 1.000‡ | 1.00 (reference) | |
| Yes | 4/12 (33.3) | 1.06 (0.25–4.45) | 0.941 | |
| Hematuria | ||||
| No | 13/39 (33.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 0/1 (0.0) | NA | 0.981 | |
| Etiology | ||||
| Cardiac or other embolism | 8/18 (44.4) | 0.379‡ | 1.20 (0.16–9.01) | 0.966 |
| Thrombosis or coagulation dysfunction | 3/16 (18.8) | 0.35 (0.04–3.08) | 0.980 | |
| Spontaneous renal artery dissection | 0/1 (0.0) | NA | 0.971 | |
| Idiopathic | 2/5 (40.0) | 1.00 (reference) | ||
|
| ||||
| eGFR at admission, per 1 ml/min/1.73 m2 | 0.74 (0.56–0.98) | 0.034 | ||
|
| ||||
| APACHE II | ||||
| ≦7 | 4/22 (18.2) | 0.033 | 1.00 (reference) | |
| >7 | 9/18 (50.0) | 4.50 (1.08–18.69) | 0.038 | |
| SOFA | ||||
| ≦1 | 3/29 (10.3) | <0.001‡ | 1.00 (reference) | |
| >1 | 10/11 (90.9) | 86.67 (8.04–934.35) | <0.001 | |
| ASA | ||||
| ≦2 | 3/26 (11.5) | <0.001‡ | 1.00 (reference) | |
| >2 | 10/14 (71.4) | 19.17 (3.61–101.91) | 0.001 | |
| SAPS II | ||||
| ≦15 | 2/21 (9.5) | 0.001 | 1.00 (reference) | |
| >15 | 11/19 (57.9) | 13.06 (2.34–72.82) | 0.003 | |
|
| ||||
| Drug therapy | ||||
| None | 4/16 (25.0) | 0.647‡ | 1.00 (reference) | |
| coumadin | 0/2 (0.0) | NA | 0.958 | |
| unfractioned heparin | 4/9 (44.4) | 2.40 (0.42–13.60) | 0.936 | |
| LMWH | 4/9 (44.4) | 2.40 (0.42–13.60) | 0.936 | |
| coumadin+UFH | 0/1 (0.0) | NA | 0.969 | |
| coumadin+LMWH | 1/1 (100.0) | NA | 0.932 | |
| coumadin+UFH+LMWH | 0/1 (0.0) | NA | 0.969 | |
| UFH+TPA(IV) | 0/1 (0.0) | NA | 0.969 | |
| Surgery | ||||
| No | 13/36 (36.1) | 0.284‡ | 1.00 (reference) | |
| Yes | 0/4 (0.0) | NA | 0.961 | |
| Blood pressure control | ||||
| No | 10/32 (31.3) | 1.000‡ | 1.00 (reference) | |
| Yes | 3/8 (37.5) | 1.32 (0.26–6.64) | 0.736 | |
| Emergent dialysis | ||||
| No | 12/39 (30.8) | 0.325‡ | 1.00 (reference) | |
| Yes | 1/1 (100.0) | NA | 0.979 | |
| Poor response to opioid | ||||
| No | 10/29 (34.5) | 1.000‡ | 1.00 (reference) | |
| Yes | 3/11 (27.3) | 0.71 (0.15–3.30) | 0.665 | |
| Pain subsided | ||||
| No | 6/22 (27.3) | 0.435 | 1.00 (reference) | |
| Yes | 7/18 (38.9) | 1.70 (0.45–6.44) | 0.437 | |
|
| ||||
| Left renal infarction | ||||
| No | 9/21 (42.9) | 0.142 | 1.00 (reference) | |
| Yes | 4/19 (21.1) | 0.36 (0.09–1.44) | 0.148 | |
| Right renal infarction | ||||
| No | 8/27 (29.6) | 0.722‡ | 1.00 (reference) | |
| Yes | 5/13 (38.5) | 1.48 (0.37–5.96) | 0.577 | |
| Bilateral renal infarction | ||||
| No | 9/32 (28.1) | 0.400‡ | 1.00 (reference) | |
| Yes | 4/8 (50.0) | 2.56 (0.52–12.48) | 0.246 | |
| Splenic infarction | ||||
| No | 11/34 (32.4) | 1.000‡ | 1.00 (reference) | |
| Yes | 2/6 (33.3) | 1.05 (0.17–6.61) | 0.962 | |
|
| ||||
| ESRD | ||||
| No | 5/21 (23.8) | 0.217 | 1.00 (reference) | |
| Yes | 8/19 (42.1) | 2.33 (0.60–9.03) | 0.222 | |
| Hospital Stay (day) | ||||
| ≦10 | 13/37 (35.1) | 0.538‡ | 1.00 (reference) | |
| >10 | 0/3 (0.0) | NA | 0.967 | |
| ICU Stay (day) | ||||
| ≦0 | 13/38 (34.2) | 1.000‡ | 1.00 (reference) | |
| >0 | 0/2 (0.0) | NA | 0.973 | |
| Ventilator use | ||||
| No | 2/18 (11.1) | 0.009 | 1.00 (reference) | |
| Yes | 11/22 (50.0) | 8.00 (1.48–43.40) | 0.016 |
Abbreviations: OR, odds ratio; CI, confidence interval; NA, non-available; CKD, chronic kidney disease; ESRD, end stage renal disease; LMWH, low molecular weight heparin; TPA, tissue plasminogen activator; UFH, unfractionated heparin.
Chi-square test; ‡Fisher's exact test.
Median served as the cutoff value.
Multivariate analysis of risk factors associated with chronic kidney disease at follow-up among patients admitted for renal infarction.
| Characteristic | Adjusted OR (95% CI) |
|
| Age (years) | ||
| ≦50 | 1.00 (reference) | |
| >50 | 7.12 (0.54–93.40) | 0.135 |
| Gender | ||
| Female | 1.00 (reference) | |
| Male | 1.23 (0.11–14.23) | 0.868 |
| SOFA | ||
| ≦1 | 1.00 (reference) | |
| >1 | 75.60 (5.62–1016.99) | 0.001 |
OR: odds ratio; CI: confidence interval.
Median served as the cutoff value.